Intervacc AB (publ) announces today that its European distribution partner, Dechra Pharmaceuticals PLC ("Dechra"), is launching Strangvac in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are expected to be available for delivery in these markets shortly.

"Strangvac is approved for sale and marketing in the EU as well as in the United Kingdom and Norway, and has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, Italy and now also in Spain, Portugal and Slovenia. These launches are important steps for the continued market development. Strangles is a serious and contagious disease affecting the equine industry throughout Europe. By offering a vaccine developed using innovative technology and based on fused recombinant proteins, we contribute to improved animal health," says Jonas Sohlman, CEO of Intervacc.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on August 18, 2025, 13.00 CET.

About Strangvac

Strangvac is a vaccine against equine strangles and is approved for sale and marketing in the EU as well as in the United Kingdom, Iceland, Norway, and Liechtenstein. It has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland and Italy.

About Dechra

Dechra Pharmaceuticals is the exclusive distribution partner of Intervacc for the Strangvac vaccine in Europe excluding the Nordic and Baltic countries. Dechra is a global specialist in veterinary pharmaceuticals and related products. Dechra has expertise in the development, manufacturing, marketing and sales of high-quality products exclusively for veterinarians worldwide.

About Intervacc
Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10